TRIB Trinity Biotech PLC ADS

Trinity Biotech to Present at Emerging Growth Conference

Trinity Biotech to Present at Emerging Growth Conference

DUBLIN, Ireland, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), today announces that management will present virtually at the Emerging Growth Conference on March 7, 2024. The Company invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. Please see the presentation information below.

Presentation Details

Date:Thursday, March 7, 2024
Time:11:25 – 11:55 AM ET
Registration:



About Trinity Biotech Plc

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website:

Contact:Trinity Biotech plc

Des Fitzgerald

(353)-1-2769800		LifeSci Partners, LLC

Eric Ribner

(1)-646-751-4363

E-mail 



EN
08/02/2024

Underlying

TRIBTrinity Biotech PLC ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Trinity Biotech PLC ADS

 PRESS RELEASE
Free
TRIB Trinity Biotech...

Trinity Biotech Publishes Fourth Quarter and Fiscal Year 2024 Financia...

Trinity Biotech Publishes Fourth Quarter and Fiscal Year 2024 Financial Results & Provides a Business Update DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2024 and the fiscal year then ended. Key Highlights and Developments Management continues to make significant progress on the execution of the profitability focused initiatives announced in 2024 as part of its...

May 15, 2025 1 EN
 PRESS RELEASE
Free
TRIB Trinity Biotech...

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global...

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement DUBLIN, March 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice today from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that listed securities maintain a minimum bid pri...

March 14, 2025 1 EN
 PRESS RELEASE
Free
TRIB Trinity Biotech...

Trinity Biotech Further Strengthens Focus on Continuous Glucose Monito...

Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process DUBLIN and PORTLAND, Ore., March 13, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose monitoring (“CGM”) technology with the appointment of Barclays Capital Inc. (“Barclays”) as...

March 13, 2025 1 EN
 PRESS RELEASE
Free
TRIB Trinity Biotech...

Trinity Biotech Announces Additional Funding To Support Transformation...

Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company’s Continuous Glucose Monitoring Technology DUBLIN, Ireland, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has obtained an additional $4m in debt financing from its primary lender, Perceptive Advisors. The additional liquidity will support both the continued development of Trinity Biotech’s innov...

February 28, 2025 1 EN
 PRESS RELEASE
Free
TRIB Trinity Biotech...

Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-P...

Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 DUBLIN, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced new findings from its latest pre-pivotal trial, highlighting significant improvements in first-day performance for its next-generation continuous gl...

February 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch